Journal · Updated 2026-08-11
The True First-Year Cost of Tirzepatide, Month by Month
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
A first year of tirzepatide is not one price — it is twelve months of decisions, and the honest annual totals span a fourfold range depending on which ones you make. Priced from our capture-dated database: a year on the current all-in compounded floor — a promotional lock-in at one hundred sixty-nine dollars monthly, one thirty-nine on the twelve-month plan — runs roughly seventeen hundred to two thousand dollars if the lock-in holds as published; a year at the compounded market's month-to-month median (independent hands-on tracking puts the average near three hundred thirty dollars across twenty-six clinics) runs close to four thousand; and the FDA-approved LillyDirect vial pathway runs five thousand one hundred to five thousand four hundred at perfect forty-five-day-window discipline — with a single missed window adding six hundred to nine hundred more. The month-by-month walk below shows where each dollar decision actually lands on the calendar, because the expensive mistakes in year one are calendar mistakes wearing price tags.
Months one through three: the titration stretch, and the trick season
The label's escalation runs 2.5 mg for four weeks, then 5 mg, then upward in four-week steps — which makes months one through three the season of every pricing trick this site catalogs, because they are the only months the starter-priced ads describe. On a dose-flat program the three months cost three times the flat rate and nothing changes at the calendar line; on a dose-tiered program they are the cheap months you are passing through; on the brand vial pathway they are the two-ninety-nine starter months before the four-forty-nine maintenance vials begin. The one purchase decision that matters here: resist annual prepayment in month one. You do not yet know your tolerability, your maintenance dose, or whether this medication is yours long-term — and a twelve-month prepaid discount is priced exactly on the bet that some buyers won't finish it, the arithmetic the prepaid-plan piece runs in full.
Months four through twelve: maintenance, where the year actually lives
By month four most weight-management patients sit at ten milligrams or above and stay there — nine months that are seventy-five percent of the year and, on tiered structures, more than that share of the cost. This is the stretch where structure outweighs sticker: the flat program's price does nothing while the tiered program's steps up; the promotional program's published end date arrives (the current floor's is August 31, with a two-fifteen standard card behind it — budget the back half of the year on the reversion unless the lock-in's terms hold your enrolled rate, both figures on the ledger); and the brand pathway's forty-five-day clock ticks nine more times, each tick carrying the six-hundred-dollar consequence of a miss. The maintenance stretch is also where a mid-year provider switch becomes tempting when a cheaper figure appears — worth doing with eyes open: transfer friction, refill-timing gaps, and a new pharmacy's verification homework are real costs the sticker doesn't show.
The honest annual totals, side by side
In words, all-in, at the maintenance basis, from the database's current captures: the promotional compounded floor's twelve-month plan totals about sixteen hundred seventy dollars at one thirty-nine monthly if held for the year; the same program month-to-month at one sixty-nine totals just over two thousand — both promotional figures whose standard-card reversions (two hundred fifteen monthly; eighty-six more per month) are the numbers to budget past the published end date. The flat mid-market — Sprout at two ninety-nine, PlexusDx's provider-stated two forty-nine, Peak's three forty-nine dropping to two thirty-two on a six-month prepaid, TrimRx and Fridays in the three-forties and fifties — books three to forty-two hundred for the year. The month-to-month market median near three thirty books just under four thousand. And LillyDirect's approved vials book five thousand three hundred eighty-eight at twelve on-window maintenance months (two starter months trim it slightly), plus the miss premium if the calendar slips. Every figure above carries its status in the database — verified, reported, provider-stated, or operator-stated — and the honest first-year budget uses the reversion rates, assumes one pricing surprise, and keeps the verification file current, because the cheapest year is the one without an unverified pharmacy in it.
Questions people ask
What does a first year of tirzepatide actually cost in 2026?
All-in, at the maintenance basis: roughly $1,670–$2,030 on the current promotional compounded floor (if its lock-in holds as published; the standard card behind it is $215/month), $3,000–$4,200 across the flat mid-market, just under $4,000 at the month-to-month market median (~$332), and $5,388 on LillyDirect's approved vials at perfect 45-day-window discipline — with one missed window adding $600–$900.
When during the year do most people overspend?
Two moments: month one, by prepaying annually before knowing their maintenance dose or tolerability, and the maintenance stretch (months four through twelve), by having chosen a dose-tiered or membership-carrying structure whose true cost only appears after titration. Both are structure decisions, not sticker decisions.
Should I budget on the promotional price or the standard price?
On the standard (reversion) price for any month past the promotion's published end date — unless the program's lock-in terms contractually hold your enrolled rate, in which case screenshot those terms at checkout. The price-change ledger prints both figures for every promotional entry.
Is the brand pathway ever the cheaper year?
Rarely on cash math alone — but insurance changes everything: a covered brand prescription with a manageable copay beats every cash figure on this page, which is why the indication-door and prior-authorization work is worth doing before defaulting to cash. The cash brand pathway's value is FDA approval, not price.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.